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ssessment of Depression
n Heart Failure Patients
hat Is the Role for Cardiology?*
ngrid Connerney, DRPH,† Peter A. Shapiro, MD‡
altimore, Maryland; and New York, New York
pproximately 5.8 million people in the United States have
eart failure (HF) (1), and a large meta-analysis estimated
he prevalence of depression in HF patients to be 21.5%
range, 9% to 60%) (2), suggesting that in the United States
oday, there are more than 1 million people with HF and
linically significant depressive symptoms. Several studies
ave established an association between depression and
dverse cardiac outcomes in patients with HF (3–7), with a
ore than 2-fold increase in the risk of death and cardiac
vents associated with depression in HF patients during a
ollow-up of 6 months to 4 years (relative risk: 2.1, 95%
onfidence interval [CI]: 1.7 to 2.6) (2).
See page 418
Most studies measuring depression and mortality in cardiac
opulations have measured depression only once, and therefore
ave not considered the effect of changes over time; however,
epression is an affective disorder with episodes that may be
hort-lived or may fluctuate in severity. Havranek et al. (8)
ound that 21% of 245 HF outpatients without depression at
aseline had significant depressive symptoms at the 1-year
ollow-up, whereas Koenig (9) reported remission within 6
onths in 48% of 157 HF patients with major depression.
lthough some researchers have looked at the course of
epression over time in HF patients, this has not been
xamined in relation to clinical outcomes.
In this issue of the Journal, Sherwood et al. (10) report the
ssociation of change in depression symptom severity over 1
ear with mortality or hospitalization in the subsequent 4
ears. Depression was assessed with the Beck Depression
nventory (BDI), at baseline and 1 year later, in 147 HF
linic patients. Change in BDI scores from baseline to 1
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Organizational Systems and Adult Health, University of
aryland School of Nursing, Baltimore, Maryland; and the ‡Department ofb
yschiatry, Columbia University College of Physicians and Surgeons, New York,
ew York. Both authors have reported that they have no relationships to disclose.ear was associated with a higher risk of the composite end
oints of cardiovascular hospitalization or mortality (hazard
atio [HR]: 1.07, 95% CI: 1.02 to 1.12, p  0.007) and
ll-cause hospitalization or mortality (HR: 1.06, 95% CI: 1.01
o 1.11, p  0.023). A strength of this study design was the
nclusion of both ejection fraction and plasma N-terminal
ro–B-type natriuretic peptide as measures of HF severity. The
levated risk for hospitalization or mortality associated with
epression was independent of standard risk factors including
ge, HF cause, ejection fraction, plasma N-terminal pro–B-
ype natriuretic peptide, and hospitalizations during the base-
ine year of assessment. In addition, the multivariate analysis
ontrolled for baseline BDI score and use of antidepressant
edications. Patients with the most marked increase in de-
ression symptoms (defined as a 3-point or more increase in
DI score) were at twice the risk of cardiovascular hospital-
zation or mortality compared with patients showing minimal
hange (HR: 2.12, 95% CI: 1.31 to 3.43, p  0.002), but not
t significantly increased risk of all-cause hospitalization or
ortality outcomes. These findings are consonant with those
f the few studies that have examined the association of
ew-onset or worsening symptoms of depression after myo-
ardial infarction with subsequent mortality (11–14).
The findings raise additional questions. The first relates
o the association of depression treatment with outcomes for
F patients. Is the use of antidepressants associated with
mproved or adverse cardiac outcomes in these patients?
lthough the study by Sherwood et al. (10) was not
esigned to focus on the safety of antidepressants in HF
atients, it found no association between antidepressant use
nd adverse clinical outcomes. Twenty percent of patients
ere taking antidepressant medication at baseline, and this
easure was included in the multivariate analysis (HR for
ardiac hospitalization or death: 0.63, 95% CI: 0.36 to 1.08,
 0.09). Similarly, O’Connor et al. (15) reported that
epression, but not antidepressant use in itself, was associ-
ted with increased mortality in 1006 patients with HF
antidepressant use HR: 1.24, 95% CI: 0.94 to 1.64, p 
.13). However, a previous study of 204 HF patients by
herwood et al. (7) demonstrated increased likelihood of
ardiovascular death or hospitalization associated with an-
idepressant medications, independent of depression sever-
ty (HR: 1.75, 95% CI: 1.14 to 2.68, p  0.01).
Recent preliminary results from a large randomized,
ontrolled trial, the SADHART-CHF (Safety and Efficacy
f Sertraline for Depression in patients with Congestive
eart Failure) trial, indicated no difference in cardiovascular
utcomes when comparing HF patients treated with sertra-
ine versus placebo (16). Similarly, well-designed random-
zed clinical trials of depression treatment in patients with
oronary disease have not demonstrated either worsened or
mproved cardiac outcomes or survival (17,18), but most
acked power to test this effect. Importantly, however,
reatment of depression in patients with cardiac disease has
een linked to at least modest reduction in depressive
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dherence (21).
Second, should cardiologists become involved? Although
epression is a significant and debilitating disease, it is under-
iagnosed and undertreated in HF patients (9,15,22). Koenig
9) reported that fewer than 50% of congestive heart failure
utpatients with major depression received treatment. The
merican Heart Association recommends that providers
creen for and treat depression in patients with coronary heart
isease (23). Although a review by Thombs et al. (19)
oncluded that there was no evidence that depression screening
nd treatment improves cardiac outcomes, they also found that
epression treatment with medication or cognitive behavioral
herapy in patients with cardiovascular disease was associated
ith improvement in depressive symptoms.
It is feasible for the cardiologist to assess patients regu-
arly for depression. There are validated and brief screening
nstruments that can facilitate rapid identification of pa-
ients with depressive symptoms. The most manageable
epression screen for the cardiologist to administer regularly
ay be a 2-item questionnaire that includes the following:
ver the past 2 weeks, have you been bothered by any of the
ollowing problems: 1) Feeling little interest or pleasure in
oing things? 2) Feeling down, depressed, or hopeless? (23).
yes answer to either question should lead to further
ssessment, and if appropriate, the cardiologist can start
reatment or refer the patient for further care.
Third, reverse causality is a possibility for the associ-
tion between depression and adverse cardiac outcomes.
limitation of the study in this issue (10) is that medical
nd cardiac risk factors were assessed only at baseline, and
e therefore do not know how changes in these factors
ay have affected depression at 1 year, or subsequent
ortality, or their relationship. Multiple physiological
nd behavioral mechanisms may underlie the association
etween depression and mortality (24,25). Further stud-
es are needed of the relationship between the course of
epression and mortality in HF patients, the mechanisms
inking depression to adverse outcomes, and the effects of
epression interventions.
In conclusion, Sherwood et al. (10) have shown that both
epression at baseline and worsening of depressive symp-
oms over time are significant risk factors for late mortality
n HF patients. These findings underscore the importance
f monitoring for depression over time in HF patients and
he need for randomized clinical trials in HF patients to
xamine the effect of depression treatment on multiple
otential outcomes and associated mechanisms.
eprint requests and correspondence: Dr. Ingrid Connerney,
ivision of Quality and Safety, University of Maryland Medical
enter, 22 South Greene Street, Box 316, Baltimore, Maryland
1201. E-mail: iconnerney@umm.edu.EFERENCES
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